Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of REGN7999 in non‑transfusion dependent β‑thalassemia with iron overload
2023-508604-37-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of REGN7999 in beta thalassemia and iron overload (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Change from baseline in liver iron concentration (LIC) by R2* MRI, Incidence of treatment-emergent adverse events (TEAEs) and 1 more. Started Apr 2025; status: completed.
02
Drugs
REGN7999
03
Conditions
beta thalassemiairon overload
Beyond the preview
Go deeper on 2023-508604-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508604-37-00.